Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome

被引:61
作者
Fairfield, WP
Finkelstein, JS
Klibanski, A
Grinspoon, SK
机构
[1] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Boston, MA 02114 USA
关键词
D O I
10.1210/jc.86.5.2020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple endocrine and metabolic consequences of human immunodeficiency virus (HN) infection exist that may contribute to bone loss in men with the acquired immune deficiency syndrome (AIDS) wasting syndrome. Recent studies suggest that anabolic strategies can increase lean body mass in men with AIDS wasting. Prior studies have not examined the effects of anabolic agents on bone mineral density (BMD) or bone turnover in these men. To determine the effects of testosterone and progressive resistance training on BMD and bone turnover in eugonadal men with AIDS wasting, we randomly assigned 54 eugonadal men with AIDS wasting (weight < 90% IBW or weight loss > 10% from preillness baseline) to receive either testosterone enanthate (200 mg/week, im) or placebo and to progressive resistance training (3 times/week) or no training in a 2 x 2 factorial study design for 3 months. The BMD of the lumbar spine, proximal femur, and total body; lean body mass; and fat mass were measured by dual energy x-ray absorptiometry. Total body scans were repeated after 12 weeks of therapy. Baseline bone turnover and BMD were compared with those in 35 age-matched healthy non-HIV-infected control subjects. Compared with controls, lumbar spine BMD (1.021 +/- 0.018 us. 1.084 +/- 0.025 g/cm(2); P = 0.04) and total hip BMD (0.951 +/- 0.017 us. 1.070 +/- 0.019 g/cm(2); P < 0.0001) were reduced in men with AIDS wasting. T-scores were lower in men with AIDS wasting at the lumbar spine (-0.62 +/- 0.17 us. - 0.07 +/- 0.23, P = 0.05) and total hip (- 0.65 +/- 0.11 us. +0.20 +/- 0.014, P < 0.0001). Total hip T scores were less than - 1.0 in 33% of men with AIDS wasting. Neither the use of protease inhibitors nor the duration of protease inhibitors use correlated with BMD. Serum osteocalcin levels were lower(3.63 +/- 0.29 vs. 4.54 +/- 0.31 nmol/L; P < 0.04) and urinary N-telopeptide excretion was higher (45.4 +/- 4.5 us. 26.8 +/- 3.0 nmol BCE/mmol creatinine; P = 0.004) in men with AIDS wasting than in controls. Lumbar spine BMD, as assessed on regional total body dual energy x-ray absorptiometry scan, increased over the 12-week treatment period in response to testosterone (+2.4 +/- 1.3 vs. -1.3 +/- 1.0%, testosterone os, placebo, respectively; P = 0.02), but not in response to training (+0.8 +/- 1.0 vs. +0.4 +/- 1.3%, training vs. no training; P = 0.70). Lumbar spine and total hip BMD are reduced in eugonadal men with AIDS wasting. Biochemical markers of bone turnover suggest that bone formation and bone resorption are uncoupled in these men. Testosterone administration, but not resistance training, over 3 months increases lumbar spine BMD in eugonadal men with AIDS wasting.
引用
收藏
页码:2020 / 2026
页数:7
相关论文
共 27 条
[1]  
Abu EO, 1997, J CLIN ENDOCR METAB, V82, P3493, DOI 10.1210/jc.82.10.3493
[2]   Androgen supplementation in eugonadal men with osteoporosis: Effects of six months' treatment on markers of bone formation and resorption [J].
Anderson, FH ;
Francis, RM ;
Peaston, RT ;
Wastell, HJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (03) :472-478
[3]   Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection:: Indication of normalization of the bone-remodeling process during highly active antiretroviral therapy [J].
Aukrust, P ;
Haug, CJ ;
Ueland, T ;
Lien, E ;
Müller, F ;
Espevik, T ;
Bollerslev, J ;
Froland, SS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (01) :145-150
[4]   Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels [J].
Bhasin, S ;
Storer, TW ;
Javanbakht, M ;
Berman, N ;
Yarasheski, KE ;
Phillips, J ;
Dike, M ;
Sinha-Hikim, I ;
Shen, RQ ;
Hays, RD ;
Beall, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (06) :763-770
[5]  
BREEN EC, 1990, J IMMUNOL, V144, P480
[6]   DESIGN CONSIDERATIONS FOR AIDS TRIALS [J].
BYAR, DP ;
SCHOENFELD, DA ;
GREEN, SB ;
AMATO, DA ;
DAVIS, R ;
DEGRUTTOLA, V ;
FINKELSTEIN, DM ;
GATSONIS, C ;
GELBER, RD ;
LAGAKOS, S ;
LEFKOPOULOU, M ;
TSIATIS, AA ;
ZELEN, M ;
PETO, J ;
FREEDMAN, LS ;
GAIL, M ;
SIMON, R ;
ELLENBERG, SS ;
ANDERSON, JR ;
COLLINS, R ;
PETO, R ;
PETO, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1343-1348
[7]   Treatments for wasting in patients with the acquired immunodeficiency syndrome [J].
Corcoran, C ;
Grinspoon, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (22) :1740-1750
[8]   RISK-FACTORS FOR HIP FRACTURE IN WHITE WOMEN [J].
CUMMINGS, SR ;
NEVITT, MC ;
BROWNER, WS ;
STONE, K ;
FOX, KM ;
ENSRUD, KE ;
CAULEY, JC ;
BLACK, D ;
VOGT, TM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (12) :767-773
[9]   ENDOCRINE DISORDERS IN MEN INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS [J].
DOBS, AS ;
DEMPSEY, MA ;
LADENSON, PW ;
POLK, BF .
AMERICAN JOURNAL OF MEDICINE, 1988, 84 (03) :611-616
[10]   INCREASES IN BONE-DENSITY DURING TREATMENT OF MEN WITH IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM [J].
FINKELSTEIN, JS ;
KLIBANSKI, A ;
NEER, RM ;
DOPPELT, SH ;
ROSENTHAL, DI ;
SEGRE, GV ;
CROWLEY, WF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 69 (04) :776-783